The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
O’Hara should have realised a long time ago that staying on Aquis restricts the share price notably on the spread but particularly that no international brokers include PBX as tradable.
That alone stops interest. Shares that are on Aquis as extra to their AIM listing for example are
unaffected. So for anyone outside UK has only expensive full service brokers to turn to and low flexibility.
It seems to be “Fiddling while Rome burns”
What happens if Probiotix did move to AIM. Would our shares automatically get moved over to AIM?
I currently have mine in a iWeb account, but as they don't offer Aquiss exchange, I would have to move them to a provider who does. I was hoping Probiotix would move to AIM.
Chased up Walbrook this am re Steen's proposed presentation on plans for 2024. Prompt reply but no date yet. I asked them to give him a nudge. :)
Research that was carried out prior to trial presumably
https://www.mdpi.com/2624-5647/6/1/8
mol
RNS to confirm Michael L appt today, and departure of Mikkel HH.
He almost seems more suited to Skinbiotix.
Https://www.dksh.com/vn-en/home/media/news?id=en-2fbb8064-beb5-43dc-8522-f0849299996b:1-lt
and we know that
https://www.loreal.com/en/press-release/research-and-innovation/loreal-acquires-research-firm-lactobio/
what will become of our commercial director?
mol
Has worked at Deerland, Bifodan and most recently, Lactobio. Another "chief"? So will have to prove his worth.
Many thanks martinu
much appreciated
mol
Michael Litichevski. Not surprisingly Danish speaker and worked with Steen and Nils before. Seems popular if number of comments (40) to his posting on LinkedIn anything to go by.
Efficacy of Cholesterol-lowering L. Plantarum on Cardiometabolic Health Biomarkers in Coeliac Disease Patients
Study Purpose
Recent studies have also shown that 30% of the world’s population carries the susceptibility genes for coeliac disease and that only 2-5% of these individuals are really affected, however, studies suggest the existence of other factors capable of contributing to the onset of the disease, such as intestinal dysbiosis. We have also seen how each of us has a specific microbiota, defined as an individual human enterotype, which depends on our background and can be modified by the diet. Recently, much interest has been directed to a strain of lactobacilli, called Lactobacillus plantarum (LP-LDL®) capable of reducing cholesterol and preventing the reabsorption of bile salts in the liver. The efficacy of this bacterial strain has been confirmed in 3 different human studies demonstrating the efficacy of LP-LDL® in patients with high baseline cholesterol (TC> 6mmol / L). This is a food supplement that has been commercially available in multiple formulations in Europe for over 3 years. LP-LDP is a probiotic strain, safe to use, selected for its high bile salt hydrolase in vitro, and in vivo cholesterol reduction activity. The intake of 2 Å~ 109 CFU encapsulated LP-LDL twice daily, significantly reduced LDL-C (13.9%), total cholesterol (TC) (37.6%), TG (53.9%), and significantly increased HDL-C (14.7%; in subjects >60 years of age; 6-12 weeks) in normal to mildly hypercholesterolaemic subjects. In a recent double-blind placebo-controlled human study published by the Journal of Functional Foods (2022) and carried out by the University of Roehampton (UK), LPLDL showcased statistically significant reductions in multiple cardiovascular risk biomarkers, including total cholesterol, LDL cholesterol, non-HDL cholesterol and apoB. No adverse effects were noted throughout the study. We are here proposing a pilot human intervention study to evaluate the effectiveness of the LP-LDL® probiotic in reducing cardiovascular risk factors inclusive of cholesterol in the blood in people with coeliac disease.
Recruiting in Italy - UK still to recruit
https://clinicaltrials.gov/study/NCT06178107
also noted on
https://trials.celiac.org/trials/NCT06178107
mol
Anyone here on linkedin and can then let us know who this is?
liked by cs and apparently joining in Jan 2024
https://uk.linkedin.com/in/chrisstephenson2020
mol
Review of seed ds-01 191223
https://www.si.com/showcase/nutrition/seed-probiotic-review
mol
Albeit perhaps no one has told Tom
https://uk.linkedin.com/in/tom-o-hara-6a8686184
lol
mol
From 14-21 nov 23 by the looks of it
URL Images Last Mod.
https://probiotixhealth.com/ 17 2023-11-21 11:35 +00:00
https://probiotixhealth.com/corporate/ 5 2023-11-14 12:37 +00:00
https://probiotixhealth.com/contact-us/ 9 2023-11-16 13:19 +00:00
https://probiotixhealth.com/lpldl/ 15 2023-11-16 16:28 +00:00
https://probiotixhealth.com/products/ 5 2023-11-16 16:47 +00:00
https://probiotixhealth.com/scientific-studies/ 1 2023-11-17 09:44 +00:00
https://probiotixhealth.com/about-us/ 9 2023-11-21 09:59 +00:00
mol
Has had a more than welcome makeover
https://probiotixhealth.com/
I tend to check the undernoted more than the above
https://probiotixhealth-ir.com/
so hadn't noticed albeit picture is familiar from this year
mol
Looks like position filled
From dec 23
Global Supply Chain Director
https://dk.linkedin.com/in/mads-brandt-96849b1?trk=people-guest_people_search-card
think director is used solely in the context of the position (sounds better - at least to some - not me) rather than a director of
probiotix health plc
which still persists in using seborg as head quarters and to this date hasn't explained the apparent subsidiary involving our CEO
https://uk.linkedin.com/company/probiotix-health?trk=public_profile_experience-item_profile-section-card_subtitle-click
mol
You will get the drift
https://www.youtube.com/watch?v=SO4Ht5gvkGQ
https://www-holos-com-hk.translate.goog/product/cholbiome-bp/?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
mol
Cheers martinu
increasing liquidity is difficult in these markets - lol
impossible on aquis
mol
Great, we get to hear from Steen a year after he took up the role
A reply to my email.
Apologies for the delay. I was on holiday when you sent the original email and it fell under my radar after I got back. The Company is working constantly on delivering milestones and increasing liquidity. The latter is difficult in these markets, but they have a defined strategy in place. For your information, we intend to hold an investor presentation (hosted on the IMC platform) in the New Year where Steen will lay out the plans for 2024 and how he and the Board plan to delivery growth.
Thanks for posting mol but as others have pointed out the company appears similar in nature to wallstreet in terms of its superficial analysis. For example "ProBiotix was spun off from Optibiotix in March 2022, and the numbers to its year end in June 2022 were for the three months after the flotation: these amounted to revenues of £306,000 and an operating loss of £256,000, and cash at that time of £2,034,000. It is a finished product company as opposed to Opti which sells ingredients. " try telling that to Seed Health who are Pbx's biggest revenue generator by far and take LPLDL as an ingredient to be incorporated in their DS01 product
Having posted re this firm on another bb (SBTX) thought i'd just have a recce re pbx
here is their take on pbx - updated as at Aug 23
https://www.lgbco.com/quoted-landing-page/the-future-of-healthcare/probiotix/
mol
Sent this today to Walbrook
Dear Probiotix,
The following is taken from the half year accounts published in Sept.
"We will continue to work with Aquis and explore opportunities on other markets, including AIM, to increase liquidity in the Company's share price."
Please will you tell me what progress has been made with regard to listing Probiotix on AIM.
Thank you
FYI I did put my name and address to email.
June 10-12 2024 Salt Lake City
https://probiotaamericas.com/live/en/page/home
we're a sponsor this year
https://probiotaamericas.com/live/en/page/sponsors
mol